公开(公告)号：US11124787B2

公开(公告)日：2021-09-21

申请号：US16262180

申请日：2019-01-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  CHILDREN'S MEDICAL CENTER CORPORATION

Inventor： Denisa D. Wagner ,  Anil Kumar Chauhan ,  Friedrich Scheiflinger ,  Barbara Plaimauer

IPC: C12N9/64 ,  A61K38/17 ,  A61K38/48

Abstract: This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.

公开(公告)号：US11185575B2

公开(公告)日：2021-11-30

申请号：US16567048

申请日：2019-09-11

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Alexandra Nathalie Kopic ,  Werner Hollriegl ,  Barbara Plaimauer ,  Hanspeter Rottensteiner ,  Eva-Maria Muchitsch

IPC: A61K38/48 ,  C12N9/64 ,  A61K9/00 ,  A61K9/19

Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.

公开(公告)号：US11779635B2

公开(公告)日：2023-10-10

申请号：US17525759

申请日：2021-11-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Alexandra Nathalie Kopic ,  Werner Hoellriegl ,  Barbara Plaimauer ,  Hanspeter Rottensteiner ,  Eva-Maria Muchitsch

IPC: A61K38/48 ,  C12N9/64 ,  A61K9/00 ,  A61K9/19

CPC classification number: A61K38/4886 ,  A61K9/0019 ,  A61K9/19 ,  C12N9/6489 ,  C12Y304/24087

Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.

公开(公告)号：US20220002703A1

公开(公告)日：2022-01-06

申请号：US17478520

申请日：2021-09-17

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  CHILDREN'S MEDICAL CENTER CORPORATION

Inventor： Denisa D. Wagner ,  Anil Kumar Chauhan ,  Friedrich Scheiflinger ,  Barbara Plaimauer

IPC: C12N9/64 ,  A61K38/17 ,  A61K38/48

Abstract: This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof